5-chlorobenzimidazole-2-carboxamide | 113115-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-chlorobenzimidazole-2-carboxamide
• 英文别名: 6-chloro-1H-benzimidazole-2-carboxamide
• CAS: 113115-61-0
• 化学式: C₈H₆ClN₃O
• mdl: MFCD18807807
• 分子量: 195.608
• InChiKey: ZLNNJSSPVHXYLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,10-二氯苯并[4,5]咪唑并[1,2-a]苯并[4,5]咪唑并[1,2-d]吡嗪-6,13-二酮 在 氨 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以77%的产率得到5-chlorobenzimidazole-2-carboxamide
  参考文献：
  名称：

  Dubey, Rashmi; Sharma, Satyavan; Popli, S. P., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1987, vol. 26, # 1-12, p. 395 - 397

  摘要：

  DOI：

文献信息

• BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S
  申请人：Allen Darin

  公开号：US20080207683A1

  公开（公告）日：2008-08-28

  Biaryl-substituted tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

  所述的双芳基取代的四氢吡唑吡啶化合物被描述为对半胱氨酸蛋白酶S的调节剂。这些化合物可用于制备药物组合物和治疗由半胱氨酸蛋白酶S活性介导的疾病状态、疾病和病况的方法，如银屑病、疼痛、多发性硬化、动脉粥样硬化和类风湿性关节炎。
• [EN] N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS<br/>[FR] N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE-CARBOXAMIDES EN TANT QU'ANTAGONISTES D'ACIDE LYSOPHOSPHATIDIQUE
  申请人：MERCK PATENT GMBH

  公开号：WO2013020622A1

  公开（公告）日：2013-02-14

  The invention provides novel substituted cyclopropane carboxamide compounds according to Formula (I), their manufacture and use for the treatment of proliferative inflammatory diseases, such as cancer, fibrosis or arthritis.

  该发明提供了根据式（I）制备的新型取代环丙烷羧酰胺化合物，其用于治疗增殖性炎症性疾病，如癌症、纤维化或关节炎。
• Novel Heterocyclic NF-kB Inhibitors
  申请人：LEBAN Johann

  公开号：US20100004258A1

  公开（公告）日：2010-01-07

  The present invention relates to compounds of the general formula (III): or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof.

  本发明涉及一般式（III）的化合物：或其与酸或碱的药学上可接受的盐，或药学上可接受的前药或其立体异构体。
• Novel heterocyclic NF-kB inhibitors
  申请人：Leban Johann

  公开号：US20060247253A1

  公开（公告）日：2006-11-02

  The present invention relates to compounds of the general formula (III) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof, wherein R 3 is H, —C(O)NR a R b , halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NR 4′ OR 5′ , NH 2 , amine, alkylamine, alkoxy, cycloalkyl, heterocycloalkyl, hydroxyalkyl, or haloalkyloxy; R 4 is H, halogen, alkyl, —C(NR 7 )NR 7 R 8 , —(CH 2 ) p aryl, —(CH 2 ) p NR 7 R 8 , —C(O)NR 7 R 8 , —N═CR 7 R 8 , —NR 7 C(O)R 8 , cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hyodroxyalkylamino, alkylamino, heteroaryl, or aryl; R 5 is halogen, alkyl, —C(NR 7 )NR 7 R 8 , —(CH 2 ) p aryl, —(CH 2 ) p NR 7 R 8 , —C(O)NR 7 R 8 , —N═CR 7 R 8 , —NR 7 C(O)R 8 , cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl.

  本发明涉及通式（III）的化合物或其药学上可接受的酸盐或碱盐，或其药学上可接受的前药或其立体异构体，其中R3为H，—C（O）NRaRb，卤素，烷基，卤代烷基，芳基，杂环芳基，OH，SH，NR4'OR5'，NH2，胺，烷基胺，烷氧基，环烷基，杂环环烷基，羟基烷基或卤代烷氧基；R4为H，卤素，烷基，—C（NR7）NR7R8，—（CH2）p 芳基，—（CH2）p NR7R8，—C（O）NR7R8，—N═CR7R8，—NR7C（O）R8，环烷基，杂环环烷基，卤代烷基，羟基烷基，羟基烷基氨基，烷基氨基，杂环芳基或芳基；R5为卤素，烷基，—C（NR7）NR7R8，—（CH2）p 芳基，—（CH2）p NR7R8，—C（O）NR7R8，—N═CR7R8，—NR7C（O）R8，环烷基，杂环环烷基，卤代烷基，羟基烷基，羟基烷基氨基，烷基氨基，杂环芳基或芳基。
• NOVEL HETEROCYCLIC NF-kB INHIBITORS
  申请人：Leban Johann

  公开号：US20100048574A1

  公开（公告）日：2010-02-25

  The present invention relates to compounds of the general formula (II): or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof.

  本发明涉及通式(II)的化合物或其与酸或碱的药物可接受盐，或药物可接受的前药，或其立体异构体。